ZymoGenetics, Serono See Positive Data
13th Nov 2006, 22:53 GMT
Biotech company ZymoGenetics said data from early-stage clinical trial show its lupus treatment atacicept was safe and tolerable.
ZymoGenetics, Serono See Positive Data related news:
- ZymoGenetics, Serono present positive results for atacicept — Pharmaceutical Business Review Latest News
- ZymoGenetics and Serono Report Detailed Positive Results From Atacicept Phase 1b Clinical Trial in Patients With Lupus — PR Newswire: All Releases
- ZymoGenetics encouraged by early results on lupus treatment — bizjournals.com Health Care:Biotechnology headlines
- Positive Signs for Bonds Abound — WSJ.com: Markets
- FTSE down as poor US data offsets upbeat results — Reuters: Shares
- FTSE lower as poor US data offsets upbeat results — Reuters: Business
- Pharmos Completes Phase 1 Study of Topical Diclofenac NanoEmulsion Cream — Orthopedics News from StratCenter.com
- Alba Therapeutics Presents Data From Positive Phase Ib Clinical Trial At The XII International Celiac Disease Symposium — Health News from Medical News Today
- Attunity Stream - Change Data Capture Platform Supports Multiple Data Sources — News Entries at Datamation Product Watch
- Amgen Releases Long-Term Enbrel Data — Bio-Technology News from StratCenter.com
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress